RyboDyn key facts
as of Oct 2026- Developer of front-running scientific breakthroughs designed to develop upgraded medicines.
- RyboDyn is valued at approximately $49.0M as of Oct 2026 (last reported valuation).
- It has raised $13.9M; the latest was Seed Round ($10.0M) in Mar 2026.
- Notable investors include SOSV, IndieBio, Massive Tech Ventures, EvoNexus, Genedant Capital — 8 tracked in total.
- Status: Privately Held (backing).
RyboDyn's last reported valuation, Mar 2026. Nothing priced has surfaced since.
- ·Watch RyboDyn: the Monday email on marks, rounds and moves
RyboDyn funding rounds
No funding rounds for RyboDyn are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
RyboDyn valuation
RyboDyn's last reported valuation was $49 million in Mar 2026. No priced round, secondary trade or fund mark has surfaced since.
RyboDyn investors
8 investors are on record for RyboDyn, including SOSV, IndieBio, Massive Tech Ventures and EvoNexus.
About RyboDyn
Developer of front-running scientific breakthroughs designed to develop upgraded medicines. The company's scientific breakthroughs a new class of treatments for far-reaching improvements, enabling individuals to get treated for terminal diseases and ailments.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2022
- Employees
- 9
- Website
- rybodyn.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.